AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2003_CD 71_CD 5_CD Taxation_NNP Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ,_, as_IN shown_VBN in_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN ,_, was_VBD as_IN follows_VBZ :_: 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD UK_NNP 879 741 618_CD Overseas_JJ 3,323_CD 3,296_CD 3,459_CD 4,202_CD 4,037_CD 4,077_CD Taxes_NNS on_IN profit_NN on_IN ordinary_JJ activities_NNS were_VBD as_IN follows_VBZ :_: UK_NNP taxation_NN Corporation_NNP tax_NN 142 165 147_CD Double_RB taxation_NN relief_NN 23_CD 29_CD 37_CD Deferred_JJ taxation_NN 102_CD 24 53 221 160_CD 163_CD Overseas_JJ taxation_NN Overseas_JJ taxes_NNS 783 929 739_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 26_CD 51_CD 17_CD Deferred_VBN taxation_NN 113 139 275 922_CD 1,017_CD 997_CD Tax_NNP on_IN profit_NN on_IN ordinary_JJ activities_NNS 1,143_CD 1,177_CD 1,160_CD UK_NNP and_CC overseas_JJ taxation_NN has_VBZ been_VBN provided_VBN at_IN current_JJ rates_NNS on_IN the_DT profits_NNS earned_VBN for_IN the_DT periods_NNS covered_VBN by_IN the_DT Group_NNP Financial_NNP Statements_NNP ._.
To_TO the_DT extent_NN that_IN dividends_NNS remitted_VBN from_IN overseas_JJ subsidiaries_NNS ,_, joint_JJ ventures_NNS and_CC associates_NNS are_VBP expected_VBN to_TO result_VB in_IN additional_JJ taxes_NNS ,_, appropriate_JJ amounts_NNS have_VBP been_VBN provided_VBN for_IN ._.
No_DT deferred_JJ tax_NN has_VBZ been_VBN provided_VBN for_IN unremitted_JJ earnings_NNS of_IN Group_NNP companies_NNS overseas_RB as_IN these_DT are_VBP ,_, in_IN the_DT main_JJ ,_, considered_VBN permanently_RB employed_VBN in_IN the_DT businesses_NNS of_IN these_DT companies_NNS and_CC ,_, in_IN the_DT case_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS ,_, the_DT taxes_NNS would_MD not_RB be_VB material_NN ._.
Cumulative_JJ unremitted_JJ earnings_NNS of_IN overseas_JJ subsidiaries_NNS and_CC related_VBN undertakings_NNS totalled_VBD approximately_RB $_$ 9,381_CD m_NN at_IN 31_CD December_NNP 2003_CD 2002_CD $_$ 9,141_CD m._FW Unremitted_JJ earnings_NNS may_MD be_VB liable_JJ to_TO overseas_JJ taxes_NNS and_CC or_CC UK_NNP taxation_NN after_IN allowing_VBG for_IN double_JJ taxation_NN relief_NN if_IN they_PRP were_VBD to_TO be_VB distributed_VBN as_IN dividends_NNS ._.
Exceptional_JJ items_NNS included_VBN in_IN tax_NN on_IN ordinary_JJ activities_NNS :_: 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Tax_NNP credit_NN on_IN exceptional_JJ items_NNS 54_CD Includes_VBZ deferred_JJ tax_NN relief_NN of_IN $_$ nil_JJ 2002_CD $_$ nil_CD ,_, 2001_CD $_$ 23m_CD ._.
Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS In_IN certain_JJ circumstances_NNS ,_, tax_NN charges_NNS or_CC credits_NNS on_IN currency_NN differences_NNS on_IN borrowings_NNS are_VBP taken_VBN to_TO reserves_NNS via_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
The_DT tax_NN charge_NN on_IN such_JJ currency_NN translation_NN differences_NNS amounted_VBD to_TO $_$ nil_CD in_IN 2003_CD 2002_CD $_$ 2m_CD ,_, 2001_CD $_$ 6m_CD and_CC has_VBZ been_VBN reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
The_DT tax_NN credit_NN on_IN other_JJ consolidation_NN exchange_NN adjustments_NNS taken_VBN to_TO reserves_NNS amounted_VBD to_TO $_$ 66m_CD 2002_CD $_$ 135m_CD ,_, 2001_CD charge_NN of_IN $_$ 36m_CD ._.
Factors_NNS affecting_VBG future_JJ tax_NN charges_NNS As_IN a_DT group_NN involved_VBN in_IN worldwide_JJ operations_NNS ,_, AstraZeneca_NNP is_VBZ subject_JJ to_TO several_JJ factors_NNS that_WDT may_MD affect_VB future_JJ tax_NN charges_NNS ,_, principally_RB the_DT levels_NNS and_CC mix_NN of_IN profitability_NN in_IN different_JJ jurisdictions_NNS ,_, transfer_NN pricing_NN policies_NNS and_CC tax_NN levels_NNS imposed_VBN ._.
In_IN 2003_CD ,_, a_DT settlement_NN was_VBD negotiated_VBN with_IN the_DT UK_NNP and_CC US_NNP governments_NNS covering_VBG all_DT liabilities_NNS potentially_RB arising_VBG from_IN transfer_NN pricing_NN in_IN respect_NN of_IN ex-Zeneca_NN products_NNS for_IN the_DT years_NNS 1987_CD to_TO 2001_CD ._.
The_DT settlement_NN had_VBD been_VBN provided_VBN for_IN in_IN previous_JJ years_NNS and_CC had_VBD no_DT impact_NN on_IN the_DT 2003_CD tax_NN charge_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 72_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 5_CD Taxation_NNP continued_VBD Tax_NNP reconciliation_NN to_TO UK_NNP statutory_JJ rate_NN The_DT table_NN shown_VBN below_IN reconciles_NNS the_DT UK_NNP statutory_JJ tax_NN charge_NN to_TO the_DT Groups_NNS current_JJ tax_NN charge_NN on_IN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ._.
2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 4,202_CD 4,037_CD 4,077_CD Notional_NNP taxation_NN charge_NN at_IN UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN 30_CD %_NN for_IN 2002_CD ,_, 30_CD %_NN for_IN 2001_CD 1,261_CD 1,211_CD 1,223_CD Differences_NNS in_IN effective_JJ overseas_JJ tax_NN rates_NNS 159 141 108_CD Capital_NNP allowances_NNS tax_NN reliefs_NNS in_IN excess_NN of_IN depreciation_NN 291 291 401_CD Untaxed_JJ reserves_NNS 51_CD 75_CD 11_CD Other_JJ timing_NN differences_NNS 168_CD 35_CD 88_CD Items_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 80_CD 49_CD 48_CD Items_NNS not_RB chargeable_JJ for_IN tax_NN purposes_NNS 88_CD 110_CD 58_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 26_CD 51_CD 17_CD Exceptional_JJ items_NNS 105_CD 28_CD Current_JJ tax_NN charge_NN for_IN the_DT year_NN 928_CD 1,014_CD 832_CD Balance_NN sheet_NN 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Deferred_VBN taxation_NN liability_NN asset_NN movement_NN At_IN beginning_NN of_IN year_NN 359_CD 212_CD 96_CD Profit_NN and_CC loss_NN account_NN 215 163 328_CD Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 155_CD 19_CD Disposal_NN of_IN subsidiary_NN undertakings_NNS 13_CD Exchange_NNP 132_CD 139_CD 39_CD At_IN end_NN of_IN year_NN 693 359 212_CD Debtors_NNS amount_NN due_JJ within_IN one_CD year_NN Note_NN 13 732 625 550_CD Debtors_NNS amount_NN due_JJ after_IN more_JJR than_IN one_CD year_NN Note_NN 13 165 226 146_CD Provisions_NNS Note_VBP 19_CD 1,590_CD 1,210_CD 908 693 359 212_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2003_CD 73_CD 5_CD Taxation_NNP continued_VBD Deferred_JJ taxation_NN The_DT amounts_NNS of_IN deferred_VBN taxation_NN accounted_VBD for_IN in_IN the_DT Group_NNP balance_NN sheet_NN ,_, before_IN netting_VBG off_IN of_IN balances_NNS within_IN countries_NNS ,_, comprised_VBD the_DT following_JJ deferred_JJ tax_NN liabilities_NNS and_CC assets_NNS :_: 2003_CD 2002_CD $_$ m_CD $_$ m_CD Deferred_VBN tax_NN liabilities_NNS UK_NNP fixed_VBN assets_NNS 501_CD 429_CD Non-UK_JJ fixed_JJ assets_NNS 735_CD 570_CD Interest_NN accruals_VBZ 18_CD 13_CD Untaxed_JJ reserves_NNS 137_CD 86_CD Pension_NN and_CC post-retirement_NN benefits_NNS 86_CD 46_CD Other_JJ 175_CD 53_CD 1,652_CD 1,197_CD Deferred_JJ tax_NN assets_NNS Intercompany_NNP inventory_NN transfers_NNS 527_CD 496_CD Non-UK_JJ fixed_JJ assets_NNS 28_CD Merger_NN ,_, integration_NN and_CC restructuring_NN charges_NNS 16_CD Accrued_VBN expenses_NNS 238_CD 243_CD Pension_NN and_CC post-retirement_NN benefits_NNS 55_CD 26_CD Other_JJ 111 57 959 838_CD Deferred_JJ tax_NN liability_NN net_JJ 693_CD 359_CD No_DT provision_NN has_VBZ been_VBN made_VBN ,_, in_IN accordance_NN with_IN FRS19_CD ,_, for_IN rolled_VBN over_IN gains_NNS amounting_VBG to_TO $_$ 140m_CD 2002_CD $_$ 126m_CD ,_, 2001_CD $_$ 75m_CD ._.
